1.09
-0.0044(-0.40%)
Currency In USD
Address
1895 Mount Hope Avenue
Rochester, NY 14620
United States of America
Phone
585 271 2700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
August 09, 2018
| Name | Title | Pay | Year Born |
| Maurice Zauderer | Co-Founder, Chief Executive Officer, President & Director | 437,286 | 1946 |
| Jill Sanchez | Chief Financial Officer | 242,151 | 1972 |
| Elizabeth E. Evans | Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine | 309,408 | 1972 |
| Ernest S. Smith | Senior Vice President of Research & Chief Scientific Officer | 339,881 | 1972 |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.